Repligen Corp (RGEN) stock
RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30132% above fair value
$172.67+10.49 (+6.47%)
Close on Nov 18, 2026Market cap $11.04BP/E –Yield –
Repligen market cap
Market capitalization is the share price multiplied by the number of shares outstanding.
Repligen's market cap was $9.74B on Nov 11, 2026, against $9.63B a year earlier. Over the last 5 years it ranged from $6.58B to $14.64B, with a median of $9.12B.
Market Cap at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $9.74B | +5.6% |
| 2025 | Dec 31, 2025 | $9.22B | +14.4% |
| 2024 | Dec 31, 2024 | $8.06B | -19.6% |
| 2023 | Dec 29, 2023 | $10.03B | +6.7% |
| 2022 | Dec 30, 2022 | $9.40B | -35.8% |
| 2021 | Dec 31, 2021 | $14.64B | +45.2% |
| 2020 | Dec 31, 2020 | $10.08B | +109.4% |
| 2019 | Dec 31, 2019 | $4.81B | +108.2% |
| 2018 | Dec 31, 2018 | $2.31B | +46.4% |
| 2017 | Dec 29, 2017 | $1.58B | +51.6% |
| 2016 | Dec 30, 2016 | $1.04B | +11.9% |
| 2015 | Dec 31, 2015 | $931.97M | +43.9% |
| 2014 | Dec 31, 2014 | $647.52M | +48.9% |
| 2013 | Dec 31, 2013 | $434.88M | +124.7% |
| 2012 | Dec 31, 2012 | $193.50M | +81.0% |
| 2011 | Dec 30, 2011 | $106.92M | -25.9% |
| 2010 | Dec 31, 2010 | $144.23M | – |
See a number that looks wrong?